Petrovsky says that the results, which are not peer-reviewed, suggest "a remarkable coincidence or a sign of human intervention."

The authors of the study, led by vaccine researcher Nikolai Petrovsky of Flinders University in Australia, used a version of the novel coronavirus collected in the earliest days of the outbreak and applied computer models to test its capacity to bind to certain cell receptor enzymes, called "ACE2," that allow the virus to infect human and animal cells to varying degrees of efficacy.

They tested the propensity of the COVID-19 virus's spike protein, which it uses to enter cells, to bind to the human type of ACE2 as well as to many different animal versions of ACE2, and found that the novel coronavirus most powerfully binds with human ACE2, and with variously lesser degrees of effectiveness with animal versions of the receptor.